Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The June 2026 pulmonology month largely tracked new conversations and data from the 

2026 American Thoracic Society (ATS) International Conference

Association of Pulmonary Advanced Practice Providers (APAPP) National Conference

, covering severe asthma, interstitial lung disease, and airway-disease management, alongside a long-anticipated regulatory decision in smoking cessation. In severe asthma, expanded phase 4 PASSAGE data presented at ATS showed that tezepelumab reduced annualized exacerbation rates by 70% (95% CI, 63 to 75) in a real-world cohort intentionally enriched for patients underrepresented in pivotal trials, including those with comorbid COPD, current or former smokers, and Black or African American patients, with consistent benefit across phenotypes and meaningful gains in lung function and quality-of-life measures. A separate ATS analysis drawn from the Multicenter AIDS Cohort Study linked long-term insulin resistance to quantitative increases in interstitial lung disease on CT, with each doubling in time-weighted insulin resistance associated with a 1.58% greater percentage of lung involvement, an effect driven primarily by ground glass opacity rather than established fibrosis and independent of HIV or diabetes status.

Ahead of a June 20, 2026, FDA decision date, David Hill, MD, of Waterbury Pulmonary Associates and chair of the American Lung Association National Board, had described cytisinicline as a potentially meaningful addition to a smoking cessation landscape unchanged since varenicline's 2006 approval, citing quit rates 3- to 4-fold higher than unassisted cessation and decades of real-world cytisine experience abroad. The agency did issue an expected Complete Response Letter citing manufacturing-related observations at a third-party facility and incomplete labeling, with no clinical efficacy or safety concerns identified; Achieve Life Sciences had already secured a new manufacturing partner and plans to resubmit in the fourth quarter of 2026. Elsewhere, a session at APAPP on the unified airway concept argued that allergic rhinitis, chronic sinusitis, and NSAID-exacerbated respiratory disease are underrecognized drivers of asthma burden, with rhinitis identified as the leading risk factor for 30-day readmission after asthma hospitalization and allergy immunotherapy highlighted as an intervention capable of reducing exacerbations by up to 75% in some studies. 

Check out this June 2026 pulmonology month in review for full coverage of these stories and more.

FDA Issues CRL for Cytisinicline NDA in Smoking Cessation

Achieve Life Sciences announced June 22, 2026, that the FDA issued a Complete Response Letter for cytisinicline, an investigational nicotinic receptor-binding alkaloid submitted as a smoking cessation pharmacotherapy, citing manufacturing-related observations from an inspection of a third-party facility and incomplete final product labeling rather than clinical deficiencies. The application was supported by phase 3 ORCA-2 and ORCA-3 trial data showing significantly greater smoking abstinence with cytisinicline vs placebo through 24 weeks, alongside safety data from more than 1500 clinical trial participants. Achieve has partnered with Adare Pharma Solutions as a new manufacturing partner and plans to resubmit the NDA in the fourth quarter of 2026, with potential approval in the first half of 2027.

Insulin Resistance Linked to Interstitial Lung Disease on CT Measures

In a Multicenter AIDS Cohort Study analysis of 517 men presented at ATS 2026, each doubling in long-term, time-weighted insulin resistance was associated with a 1.58% greater percentage of lungs with interstitial lung disease features on CT (95% CI, 0.38 to 2.78), an association driven primarily by ground glass opacity rather than fibrosis and unaffected by HIV or diabetes status. Investigator Sarath Raju, MD, of Johns Hopkins University, said the predominance of ground glass over established scarring may point to metabolic inflammation as an early, modifiable precursor to fibrotic lung disease. The findings suggest a potential role for targeting insulin resistance before the onset of overt diabetes as a lung disease prevention strategy, pending validation in larger cohorts.

Tezepelumab Reduces Severe Asthma Exacerbations in Phase 4 PASSAGE

Phase 4 PASSAGE data presented at ATS 2026 showed that tezepelumab reduced annualized asthma exacerbation rates by 70% (95% CI, 63 to 75) in a 286-patient real-world cohort intentionally designed to reflect populations underrepresented in randomized trials, including patients with comorbid COPD, current or former smokers, and Black or African American patients. Njira Lucia Lugogo, MD, of the University of Michigan, told HCPLive that the consistency of benefit across phenotypes — alongside improvements in lung function and patient-reported outcomes — should give clinicians confidence to expand biologic use in broader, more representative patient populations. Serious adverse events occurred in 9.8% of patients, consistent with tezepelumab's established safety profile.

Unified Airway Practice: Rhinitis, Nasal Polyps, and NERD as Drivers of Asthma Burden

At the APAPP National Conference, Heather O'Connell, PA-C, MS, of Arizona Asthma and Allergy Institute, outlined the unified airway concept, under which allergic rhinitis, chronic sinusitis, and asthma represent a single inflammatory process rather than separate diseases requiring siloed management. She cited data identifying allergic rhinitis as the most prevalent risk factor for 30-day readmission following asthma hospitalization and noted that allergy immunotherapy has shown up to a 75% reduction in exacerbations in some studies. O'Connell also highlighted NSAID-exacerbated respiratory disease as a frequently missed diagnosis given declining NSAID use, recommending clinicians proactively screen patients with severe asthma and nasal polyps for a temporal link between exacerbations and NSAID exposure.

Anticipating Cytisinicline: First New Smoking Cessation Aid in Over 20 Years

Ahead of the FDA's June 20, 2026, decision date, David Hill, MD, of Waterbury Pulmonary Associates and chair of the American Lung Association National Board, discussed cytisinicline's potential as the first new smoking cessation pharmacotherapy approved since varenicline in 2006. Hill noted quit rates in the 15% to 20% range — a 3- to 4-fold improvement over the roughly 5% sustained abstinence seen with unassisted cessation — and pointed to decades of real-world experience with the structurally related compound cytisine across Eastern Europe and approximately 30 other countries as added reassurance. He also highlighted cytisinicline's Breakthrough Therapy designation for vaping cessation, an indication with no currently approved pharmacotherapy, and emphasized that any pharmacologic quit attempt should be paired with counseling and structured behavioral support.

Articles

June 2026 pulmonology updates centered on ATS and APAPP data spanning severe asthma biologics, metabolic risk factors for interstitial lung abnormalities, unified airway management, and smoking cessation regulation. Real-world PASSAGE findings showed tezepelumab substantially reduced exacerbations and improved patient-reported outcomes in populations typically excluded from pivotal trials, including smokers and patients with COPD. CT-based epidemiology linked long-term insulin resistance to greater interstitial lung disease burden, mainly ground-glass change, suggesting a potentially modifiable inflammatory precursor. Cytisinicline’s NDA received an FDA CRL for manufacturing/labeling issues, with resubmission planned.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonary Fibrosis

5 Pulmonology Headlines You Missed in June 2026

The Role of Dermatologists and APPs in Diagnosing CSU

In this episode titled “The Role of Dermatologists and APPs in Diagnosing CSU,” the moderator and panelist turn to the formal workup for inducible urticaria and the broader question of who should be diagnosing CSU. The panelist describes the textbook dermatographometer, a small card with multiple pressure-calibrated tines used to elicit a line of hives, though a simple stroke test with the thumb is used instead in practice. The formal ice-cube test for cold urticaria is also described, placing an ice cube on the skin for several minutes and observing for delayed hives, though history alone is usually sufficient and physical challenge testing is rarely necessary.

Asked about the respective roles of dermatologists and advanced practice providers in diagnosing CSU, the panel argues there is no meaningful distinction, noting that what matters most is the clinician’s attentiveness rather than their specific title, and that APPs, who often have longer appointment times, may be especially well positioned to catch the diagnosis. Both speakers stress the importance of keeping CSU on the differential whenever a patient describes recurring, unpredictable hives, since the condition is frequently misdiagnosed as an acute allergic reaction in urgent care or emergency settings, and diagnostic delays of up to two years, with symptoms sometimes persisting past five years, are common.

A case is shared of a psoriasis patient whose undiagnosed CSU led to repeated, unnecessary courses of systemic corticosteroids before being correctly identified and started on an effective targeted therapy. The episode closes with reassurance that most patients are forthcoming, rather than minimizing, about how significantly CSU affects their daily lives, underscoring the importance of timely recognition and treatment. In the next episode, “Updated Guidelines and the Current CSU Treatment Landscape,” the panel reviews the newly updated international guideline and walks through how shared decision-making is used to match patients to one of three advanced therapy options.

Videos

In this episode titled “The Role of Dermatologists and APPs in Diagnosing CSU,” the moderator and panelist turn to the formal workup for inducible urticaria and the broader question of who should be diagnosing CSU. 

Video Series

A Practical Diagnostic Workup for CSU

This episode titled “A Practical Diagnostic Workup for CSU,” covers the practical approach to evaluating patients with recurrent hives. Because lesions are often absent during office visits, the panelist frequently asks patients to photograph their hives, calling smartphone images the most valuable diagnostic tool available. When hives are present or documented, the key differential is urticarial vasculitis, distinguished from CSU using three targeted questions: whether lesions burn rather than itch, whether they leave residual discoloration or bruising, and whether an individual lesion persists longer than 24 hours, a question phrased carefully by asking patients to mentally circle one wheal and track whether that specific lesion remains the next day.

The panelist notes that while guidelines recommend baseline labs such as a CBC and ESR, extensive workups are rarely ordered unless atypical features, like fevers, chills, or joint pain, raise suspicion for an autoinflammatory process. IgE testing is similarly dismissed, since neither total IgE levels nor allergen-specific panels are clinically useful in CSU and often introduce misleading red herrings that delay appropriate treatment.

The discussion shifts to quality of life, noting that while urticaria scores lower than atopic dermatitis on itch intensity, it carries a greater overall quality-of-life burden because of its unpredictable, rapidly waxing and waning nature. Many patients avoid scheduling important events for fear of a flare, and the panel notes a clear bidirectional relationship between stress and disease activity. The takeaway is that CSU remains fundamentally a clinical diagnosis built on history and visual recognition, allowing treatment to begin promptly rather than being delayed by unnecessary testing. In the next episode, “The Role of Dermatologists and APPs in Diagnosing CSU,” the panel discusses formal testing for inducible urticaria and why timely recognition by any attentive clinician, regardless of title, is what truly protects patients from years of delayed diagnosis.

This episode titled “A Practical Diagnostic Workup for CSU,” covers the practical approach to evaluating patients with recurrent hives. 

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 and immunology specialists have a packed month to catch up on, from late-breaking hereditary angioedema (HAE) data to a first-in-class peanut allergy trial in infants. This roundup covers the latest phase 2 and phase 3 developments, key clinical pearls from the

 in Palm Beach, and a closer look at the everyday realities of living with food allergy.

Below, find summaries on lonvoguran ziclumeran's phase 3 HAELO trial results, DBV Technologies' THRIVE study, early allergen introduction guidance, chronic spontaneous urticaria (CSU) treatment sequencing, and a new resource bridging clinical care and patient experience.

 Lonvo-z cut moderate/severe HAE attacks by 91% with zero non-responders, per EAACI 2026 data.

 DBV Technologies screens first infant for Viaskin Peanut patch study in 6- to 12-month-olds.

 Routine pre-introduction testing isn't recommended for most infants, says Dartmouth's Marcus Shaker, MD.

 Jonathan Bernstein, MD, outlines when to move beyond omalizumab to dupilumab or remibrutinib.

 FAACT's "Food Allergies in the City" microdrama spotlights the social realities of food allergy management.

HAELO Phase 3: Lonvo-z Secondary Endpoints, QoL Data Detailed at EAACI

New secondary endpoint data from the phase 3 HAELO trial, presented at EAACI 2026 and published in the New England Journal of Medicine, showed lonvoguran ziclumeran (lonvo-z, Intellia Therapeutics) reduced moderate/severe HAE attacks by 91% and on-demand treatment use by 89% versus placebo, with no non-responders across the treatment arm. Patients also reported a 17.04-point improvement in Angioedema Quality of Life (AE-QoL) scores, exceeding the 6-point threshold for clinical meaningfulness.

All treatment-emergent adverse events were mild to moderate, with no liver function abnormalities observed. A rolling BLA submission is underway, with US approval anticipated in the first half of 2027.

DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial

DBV Technologies screened the first infant in THRIVE, a phase 2 trial assessing the Viaskin Peanut patch in infants aged 6 through 12 months with peanut allergies, led by investigator Douglas Mack, MD (McMaster University). The single-arm, open-label study targets ad libitum peanut consumption as its primary endpoint, requiring daily epicutaneous immunotherapy for 36 months before a peanut food challenge. THRIVE builds on desensitization data from DBV's EPITOPE and VITESSE trials in older cohorts, representing the youngest population studied with this scale of peanut allergy trial; safety monitoring will focus on local site reactions.

Early Allergen Introduction in Infants: Reducing Food Allergy Risk Without Routine Testing

Marcus Shaker, MD (Dartmouth Geisel School of Medicine), discussed early allergenic food introduction as a key food allergy prevention strategy. Shaker emphasized that routine allergy testing before introducing foods like peanuts is not recommended for most infants, since positive results do not reliably predict clinical allergy and may lead to unnecessary dietary restrictions. He advocated for individualized, shared decision-making that weighs family history, risk factors, and parental concerns, noting current practice parameters support a conditional recommendation for early introduction based on the strength of existing evidence.

Sequencing Emerging Therapies in CSU, With Jonathan Bernstein, MD

Jonathan Bernstein, MD (University of Cincinnati, Bernstein Allergy Group), outlined CSU treatment sequencing, recommending high-dose antihistamines up to 4 times the standard dose before confirming treatment failure. Updated guidelines are expected to continue favoring omalizumab as preferred next-line therapy, though patients with low IgE levels and autoimmune features may warrant alternatives like dupilumab or remibrutinib.

Bernstein noted biomarkers such as total IgE, thyroid peroxidase antibodies, and the CU Index are not yet guideline-incorporated but should be obtained before omalizumab initiation. Meanwhile, cyclosporine remains reserved for difficult-to-treat, later-line cases.

FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life

FAACT released Food Allergies in the City, a 4-episode microdrama produced with Genentech and Novartis, featuring 5 real young adults aged 18 to 23 years with food allergies navigating dating, dining out, and social situations in New York City. Lisa Horne, FAACT director of marketing, said the series surfaces topics rarely discussed in clinical visits, including kissing and social embarrassment, despite their relevance to anaphylaxis risk. Horne suggested clinicians use the series as a waiting room or patient portal resource and recommended open-ended questions, such as asking how food allergies affect daily life, to prompt deeper conversations.

Late-stage advances spanned hereditary angioedema prophylaxis, infant peanut epicutaneous immunotherapy, and practice updates in food allergy prevention and chronic spontaneous urticaria management. In phase 3 HAELO, lonvoguran ziclumeran demonstrated marked reductions in moderate/severe attacks and rescue medication use, alongside clinically meaningful AE-QoL gains and a favorable safety profile, supporting a rolling BLA with anticipated US action in 2027. Conference highlights reinforced early allergen introduction without routine pretesting, nuanced CSU sequencing beyond omalizumab, and integrating patient lived experience into care.

HAE gene editing, peanut patch trials, CSU sequencing, and EAC 2026 highlights in this allergy/immunology roundup for clinicians.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

5 Allergy Headlines You Missed in June 2026

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

Live podcast episode of ABCs in Dermatology recorded at Revolutionizing Atopic Dermatitis 2026

 ABCs in Dermatology: Updates in Atopic Dermatitis at RAD 2026

New analyses are adding momentum to early systemic intervention in moderate-to-severe 

, with growth outcomes emerging as a previously underappreciated marker of disease control in children. The findings reinforce a broader shift across the AD biologic class toward measuring success beyond skin clearance alone.

, co-hosts Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discussed the maturing interleukin-4 (IL-4)/interleukin-13 (IL-13) biologic landscape in AD. The conversation, recorded live at the 

Revolutionizing Atopic Dermatitis (RAD) 2026 meeting

 in Nashville, Tennessee, spanned dupilumab (Dupixent), tralokinumab (Adbry), and lebrikizumab (Ebglyss).Because no head-to-head trials exist among the 3 agents, comparative efficacy data rely on indirect network meta-analyses. 

Roughly 30% of patients reach Eczema Area and Severity Index (EASI) 90 or Investigator Global Assessment (IGA) 0/1 by week 16, with response rates continuing to climb well beyond this early window. In dupilumab's long-term extension trial, more than 90% of patients who had not reached EASI 75 by week 16 achieved it by week 100. 

None of the 6 FDA-approved advanced AD therapies require routine laboratory monitoring, and tralokinumab and dupilumab have each published 5-year safety data showing predominantly mild to moderate adverse events without new safety signals. 

By contrast, around 1 in 5 patients with moderate to severe AD still receive oral corticosteroids. Even a 6-day prednisone dose pack raises the risk of sepsis, bone fracture, and venous thromboembolism for 30 days afterward.Pediatric growth emerged as a focal point. Extension data from the Liberty AD PS trial showed children treated early with dupilumab had a 3.7- to 4.2-fold greater likelihood of meaningful growth improvement versus peers on no systemic therapy, independent of corticosteroid exposure. Bunick described the underlying mechanism as likely multifactorial, reflecting reduced inflammation, lower corticosteroid use, and improved sleep.

Itch tracks closely with quality of life: registry data show quality of life drops sharply unless itch reaches a 0 or 1 on a 10-point scale. This prompted both hosts to counsel patients toward this stricter target rather than partial relief. Collectively, the data point to a biologic class no longer competing only on skin clearance, but increasingly on durability, safety, and capacity to address the systemic burden of AD across the lifespan.

Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Podcasts

New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

ABCs in Dermatology: Updates in Atopic Dermatitis Live at RAD 2026

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This episode covers the recent commercial availability of the Pivot patch pump and the upcoming 7-day bolus patch from CeQur.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Evolving Wearable Insulin Delivery Devices - AID, CGM, and More

The status was granted off of data from Swedish snus — a smokeless tobacco product with similar use topography, nicotine content, pH, and systemic nicotine exposure.

FDA News

FDA Grants ZYN Nicotine Pouches Modified Risk Status Compared to Cigarettes

Frieden shares practical tips on repurposing topical timolol and sirolimus for pediatric skin conditions.

Pearls for Using Drugs for Common Conditions, With Ilona Frieden, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Saakshi Khattri, MD, discusses how real-world comparative effectiveness data suggest a potential class-level signal for risankizumab and IL-23 inhibition in reducing the risk of psoriatic arthritis among patients with psoriasis.

Real-World Data on Risankizumab and Psoriatic Arthritis Prevention in Psoriasis

Blumenthal discusses his presentation at the 10th Annual Heart in Diabetes meeting, in which he compared the current US and European dyslipidemia guidelines.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD

Gideon Hirschfield, FRCP, PhD, discusses phase 2b results from VISTAs, evaluating volixibat in PSC


Hepatology

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care

Rajani Katta, MD, clinical professor of dermatology at McGovern Medical School, University of Texas

Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Diet and Dermatology: What to Say When Your Patients Ask

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis

In, ‘Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk’, panelists will continue their discussion on hypercortisolism and highlight how cortisol excess can contribute to hypertension and cardiovascular risk even in the absence of classic Cushing syndrome features. They also explore emerging evidence linking hypercortisolism to adverse cardiometabolic outcomes and the implications for cardiovascular practice.

Latest News

5 Pulmonology Headlines You Missed in June 2026

The Role of Dermatologists and APPs in Diagnosing CSU

A Practical Diagnostic Workup for CSU

5 Allergy Headlines You Missed in June 2026

ABCs in Dermatology: Updates in Atopic Dermatitis Live at RAD 2026